RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (China), Breakthrough Therapy (United States)

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

Sequence Code 319466156

Source: *****

Sequence Code 1190395904

Source: *****

Clinical Trials associated with Plozasiran

NCT06880770

/ RecruitingPhase 3

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Start Date24 Apr 2025

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

NCT06822790

/ RecruitingPhase 3

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133).
Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of <=10% within 30 days prior to Day 1.
Subjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria:
1. HbA1c ≤10% within 30 days prior to Day 1
2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d)
3. Baseline fasting TG level of ≥500 mg/dL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001
4. Baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-2001
All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.

Start Date09 Apr 2025

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

NCT06347016

/ Active, not recruitingPhase 3

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Start Date23 Jul 2024

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

100 Clinical Results associated with Plozasiran

100 Translational Medicine associated with Plozasiran

100 Patents (Medical) associated with Plozasiran

Literatures (Medical) associated with Plozasiran

01 Dec 2025·Current Atherosclerosis Reports

Novel Therapeutics for Familial Chylomicronemia Syndrome

Review

Author: Izar, Maria Cristina ; Fonseca, Francisco Antonio Helfenstein

PURPOSE OF REVIEW:

This review discusses new treatment approaches for familial chylomicronemia syndrome (FCS), a rare disorder affecting triglyceride metabolism. The focus is on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapies targeting APOC3 and angiopoietin-like protein 3 (ANGPTL3).

RECENT FINDINGS:

Volanesorsen, an ASO targeting APOC3, has shown effectiveness in managing FCS, multifactorial chylomicronemia, and familial partial lipodystrophy, but its use is limited by thrombocytopenia. Emerging therapies, Olezarsen (ASO anti-APOC3) and Plozasiran (siRNA anti-APOC3), both conjugated with GalNAc, show promise in reducing acute pancreatitis risk without platelet concerns. ANGPTL3 inhibition requires residual lipoprotein lipase (LPL) activity, with only siRNA-based therapies-zodasiran and solbinsiran-under investigation. Suppressing APOC3 expression and targeting ANGPTL3 via siRNA offer significant potential, but long-term studies are needed to confirm their efficacy and safety. Future research may explore gene-editing strategies using lipid nanoparticle-based CRISPR-Cas9 delivery for more durable treatment outcomes.

01 Dec 2025·Current Atherosclerosis Reports

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

Review

Author: Vaughan, Elizabeth M ; Kalra, Dinesh K ; Khoja, Adeel ; Inam, Maha ; Sheikh, Sana ; Talha, Khawaja M ; Virani, Salim S ; Minhas, Abdul Mannan Khan ; Meloche, Chelsea ; Slipczuk, Leandro ; Krittanawong, Chayakrit ; Junaid, Vashma ; Hinkamp, Colin

PURPOSE OF REVIEW:

To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress.

RECENT FINDINGS:

Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

01 Dec 2025·Current Atherosclerosis Reports

Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease

Review

Author: Tsimikas, Sotirios

Abstract:

Purpose of Review:

Apolipoprotein C-III (apoC-III) is a central regulator of triglyceride metabolism. Elevated triglyceride levels are associated with increased risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD).

Recent Findings:

Conventional triglyceride-lowering therapies, such as fibrates and omega-3 fatty acids, have limited efficacy in reducing triglycerides and in reducing the risk of pancreatitis or ASCVD in patients with severe hypertriglyceridemia. ApoC-III inhibits lipoprotein lipase and impairs clearance of both triglyceride-rich and cholesterol-rich lipoproteins. Novel therapies targeting APOC3 mRNA to reduce triglycerides, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), achieve greater triglyceride reductions than standard agents. Volanesorsen and olezarsen, both ASOs, are approved as an adjunct to diet to reduce triglycerides in familial chylomicronemia syndrome (FCS) in different regions. Plozasiran, an siRNA, is in late-stage clinical development. Indirect cross-trial comparisons were performed, aligned by timepoint and outcome measures, and indicate comparable efficacy of olezarsen and plozasiran in patients with chylomicronemia.

Summary:

APOC3 inhibition is now an established therapeutic approach for reducing the risk of acute pancreatitis in FCS, with three agents, volanesorsen, olezarsen, and plozasiran, demonstrating efficacy. However, its role in ASCVD prevention remains unproven. This review evaluates current APOC3 – targeted therapies for FCS, including available comparative data, and synthesizes the emerging literature on the potential of APOC3 inhibition to reduce the burden of acute pancreatitis in broader populations with severe hypertriglyceridemia, as well as its potential role in ASCVD risk reduction.

104

News (Medical) associated with Plozasiran

27 Jan 2026

·www.businesswire.com

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes. This represents an important step forward for the field of RNAi therapeutics, as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead’s innovative and proprietary Targeted RNAi Molecule (TRiM™) platform. Arrowhead is at the forefront of innovation in the RNAi field, and we’re proud of the versatile capabilities of our TRiM platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule Mixed hyperlipidemia is a highly prevalent disorder characterized by elevated levels of both low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), and is a major risk factor for ASCVD, which is the leading cause of mortality worldwide and associated with substantial morbidity and healthcare costs. Despite the efficacy of LDL-C-lowering therapies in reducing ASCVD risk, there remains substantial residual risk in patients with mixed hyperlipidemia. “Arrowhead is at the forefront of innovation in the RNAi field, and we’re proud of the versatile capabilities of our TRiM™ platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule,” said Chris Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes, which together have substantial clinical validation as important targets for reducing LDL-cholesterol, triglycerides, and total atherogenic lipoproteins. We see ARO-DIMER-PA as having the potential to reduce the risk of ASCVD for people living with mixed hyperlipidemia, and we are excited to see what this study may reveal about the possibility of creating other dual-functional RNAi molecules for potentially treating complex genetic diseases.” The initiation of the clinical study for ARO-DIMER-PA is the latest advance in Arrowhead’s growing focus on RNAi therapeutics in the cardiometabolic therapeutic area – a portfolio that includes the company’s commercial product REDEMPLO® (plozasiran), now approved in the U.S., Canada, and China for the treatment of familial chylomicronemia syndrome (FCS), the ongoing Phase 3 study of zodasiran in homozygous familial hypercholesterolemia (HoFH), and ongoing Phase 1/2 studies of investigational ARO-INHBE and ARO-ALK7 being developed as potential treatments for obesity. Preclinical data on ARO-DIMER-PA were previously presented at the National Lipid Association (NLA) 2025 Annual Scientific Sessions and may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About ARO-DIMER-PA ARO-DIMER-PA is a dual-functional RNAi molecule designed to silence expression of both PCSK9 and APOC3 genes in hepatocytes. Prior clinical experience with other investigational and approved agents suggests that PCSK9 and APOC3 inhibition may lead to robust reductions in LDL-C, TGs, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins. ARO-DIMER-PA is the first clinical candidate designed to selectively silence the expression of two genes with a single RNAi molecule. About the ARO-DIMER-PA-1001 Phase 1/2a Study ARO-DIMER-PA-1001 (NCT07223658) is a Phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMER-PA (part 1) and multiple doses of ARO-DIMER-PA (part 2) in up to 78 adult subjects with mixed hyperlipidemia. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.

Drug ApprovalPhase 3

23 Jan 2026

·www.fiercepharma.com

ST Pharm inks $56M deal to produce API for a US biotech

Korea's ST Pharm has signed a contract worth $56 million with an unidentified U.S. biotech to produce active pharmaceutical ingredients for a new treatment for severe hypertriglyceridemia. ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an upcoming oligonucleotide-based treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.The agreement nets ST 82.5 billion Korean won ($56 million) to produce raw materials for an upcoming oligonucleotide asset for severe hypertriglyceridemia and runs from Jan. 22 to Dec. 18 of this year, according to the filing. The deal is significant for the 43-year-old manufacturer as the amount ST won is equal to 30% of its revenue from its most recent fiscal year—274 billion won ($187 million) in 2024.Specializing in the production of oligonucleotides, ST Pharm is well positioned for growth. The company has responded to increased demand for the RNA snippets by establishing its second oligonucleotide production facility last year, according to local news outlet Korea Biomedical Review. Oligonucleotides are used as synthetic building blocks for treatments that modulate gene expression.The oligonucleotide market, which stood at $10.5 billion in 2025, is projected to grow to $24.7 billion by 2030, according to MarketsandMarkets Research. Multiple approved oligonucleotide-based therapies have already hit the market via companies like Alnylam and Biogen.Meanwhile, Ionis and Arrowhead both recently scored FDA approvals for the oligonucleotide-based therapies Tryngolza and Redemplo, respectively, in the genetic high triglyceride condition familial chylomicronemia syndrome. Arrowhead has said it is further developing its small interfering RNA therapy Redemplo in severe hypertriglyceridemia, while APOC-III-directed antisense oligonucleotide Tryngolza won an FDA breakthrough tag in the indication in December.

OligonucleotideDrug ApprovalBreakthrough TherapyClinical Study

18 Jan 2026

·www.globenewswire.com

Myqorzo and Redemplo approved in China

Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. “We are pleased to bring Myqorzo and Redemplo to patients in Greater China. Both medicines represent important advances in treatment options and address unmet medical needs among people living with complex conditions,” said Olivier Charmeil, Executive Vice President, General Medicines, Sanofi. “The latest approvals underscore Sanofi’s long-term commitment to bringing innovative medicines to Chinese patients.” Myqorzo is a selective, small-molecule cardiac myosin inhibitor to improve functional capacity and relieve symptoms in patients with oHCM, in which the myocardium, the heart muscle, becomes abnormally thick. It is the most common monogenic inherited cardiovascular disorder. The approval was based on the positive pivotal SEQUOIA-HCM phase 3 study (clinical study identifier: NCT05186818) in patients with symptomatic oHCM. Redemplo is a small-interfering RNA (siRNA) medicine, suppressing the production of apoc-III, an important target for reducing triglycerides in patients with FCS. FCS is a severe and rare disease where extremely high triglyceride levels can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. The approval was based on the positive pivotal PALISADE phase 3 study (clinical study identifier: NCT05089084) in patients with genetically confirmed or clinically diagnosed FCS. HCM is the most common inherited cardiovascular disorder, characterized by abnormal thickening of the heart muscle (myocardium). This leads to the left ventricle becoming smaller and stiffer, impairing its ability to relax and fill with blood, limiting the heart’s pumping function and exercise capacity. HCM symptoms include: chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM has two forms: oHCM (two-thirds of patients), where thickened muscle blocks blood flow, and non-obstructive HCM (one-third), where the muscle is thickened but blood flows normally. HCM patients face serious complications including atrial fibrillation, stroke, and mitral valve disease. It's a leading cause of sudden cardiac death in young people and athletes due to dangerous heart rhythm abnormalities. Some patients have a high risk of progressive diseases leading to dilated cardiomyopathy and heart failure requiring transplantation. Myqorzo (aficamten) is a selective, small-molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties. Myqorzo was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with HCM. In preclinical models, Myqorzo reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state. Myqorzo is approved in the US and China. Myqorzo, for the treatment of symptomatic oHCM, was designated breakthrough therapy and orphan drug in the US, and breakthrough therapy in China. On December 12, 2025, The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization in the EU with a final decision expected in the first quarter of 2026. In December 2024, Sanofi obtained exclusive rights to develop and commercialize Myqorzo in Greater China for treating both forms of HCM. These rights came through an agreement with Corxel Pharmaceuticals, who had acquired them from Cytokinetics. FCS is a severe and rare disease leading to extremely high triglyceride levels, over 880 mg/dL (9.94 mmol/L). Such severe elevations can lead to various serious signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Redemplo (plozasiran) is a siRNA medicine suppressing the production of apoC-III, a protein produced primarily in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, Redemplo delivers significant reductions in triglyceride levels. Redemplo has been studied in both genetically confirmed and clinically diagnosed patients living with FCS. Redemplo, for the treatment of FCS, was designated breakthrough therapy, fast track, and orphan drug in the US, orphan in the EU, and breakthrough therapy in China. Redemplo is approved in the US, Canada, and China for the treatment of FCS patients. Regulatory review is ongoing in the EU. In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals. Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. The content above comes from the network. if any infringement, please contact us to modify.

Orphan DrugDrug ApprovalBreakthrough TherapyFast Track

100 Deals associated with Plozasiran

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Familial chylomicronaemia syndrome	United States	Arrowhead Pharmaceuticals, Inc.	18 Nov 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertriglyceridemia	NDA/BLA	Canada	Arrowhead Pharmaceuticals, Inc.	01 Jul 2025
Hyperlipoproteinemia Type I	Phase 3	United States	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Japan	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Argentina	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Australia	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Austria	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Belgium	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Canada	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Croatia	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	France	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05089084 (PALISADE, CTgov)	Phase 3	Hyperlipoproteinemia Type I	75	Plozasiran (ARO-APOC3 (Plozasiran) 25 mg)	gduxidbisi(xzzlewpket) = zfkfxhppfo tydnihlspa (lszvhyxagr, qohbpldawh - nqnibuhsyj) View more	-	04 Feb 2026
				Plozasiran (ARO-APOC3 (Plozasiran) 50 mg)	gduxidbisi(xzzlewpket) = rwycakjzzv tydnihlspa (lszvhyxagr, hiqpcryapr - fmnpvujpbv) View more
NCT05089084 (FDA_CDER) Manual	Phase 3	Familial chylomicronaemia syndrome	51	REDEMPLO 25 mg	sjjtuybyzv(rhvzicsobn) = fzorycvhfd zbjwtbmvjg (rikuswvdft ) View more	Positive	18 Nov 2025
				Placebo (pooled)	sjjtuybyzv(rhvzicsobn) = hsjkqfwfrv zbjwtbmvjg (rikuswvdft ) View more
NCT05757596 (Pubmed \| Cardiovasc Diabetol) Manual	Phase 1	-	24	Plozasiran 25 mg	ueebudfhra(voecsvxmsn) = eqvxejmpgt xpxszlhfpw (nkdjdhbnzb ) View more	Positive	15 Oct 2025
				Plozasiran 50 mg	ueebudfhra(voecsvxmsn) = tsmckycjzs xpxszlhfpw (nkdjdhbnzb ) View more
NCT05089084 (PALISADE, Corporate Publications \| ESC2025) Manual	Phase 3	Familial chylomicronaemia syndrome	-	Plozasiran (switched fr placebo)	xxqascjaje(vknbpkpwur) = gdifhxwwwd quykelehiv (fgmpxykvgl ) View more	Positive	30 Aug 2025
				Plozasiran (continuous treated)	xxqascjaje(vknbpkpwur) = mwsqqdxlgb quykelehiv (fgmpxykvgl ) View more
NCT05902598 \| CTR20231418 (PRNewswire) Manual	Phase 3	Familial chylomicronaemia syndrome	37	VSA001 25 mg	whcgioubla(izmhnpmxqv) = zolxleovli tzbxwwdntq (jbpizwvukg ) Met View more	Positive	17 Mar 2025
				VSA001 50 mg	whcgioubla(izmhnpmxqv) = wejmpvbkie tzbxwwdntq (jbpizwvukg ) Met View more
NCT05089084 (PALISADE, Company_Website) Manual	Phase 3	Familial chylomicronaemia syndrome	75	Plozasiran 25 mg	kaxqepxneq(tndnfowcqp) = cibvjbijpe obslawrsdh (choopbyjfx ) View more	Positive	18 Nov 2024
				Plozasiran 50 mg	kaxqepxneq(tndnfowcqp) = ntwierzfhy obslawrsdh (choopbyjfx ) View more
NCT04998201 \| NCT04720534 (MUIR, Company_Website) Manual	Phase 2	Hypertriglyceridemia \| Hyperlipidemia, Familial Combined	418	Plozasiran (MUIR)	yxyopprecq(xhrbfnrfhb) = gpgbmbhpar sikotvxbok (cbjmrkywhe )	Positive	18 Nov 2024
				Plozasiran (SHASTA-2)	yxyopprecq(xhrbfnrfhb) = ajafdjyqad sikotvxbok (cbjmrkywhe )
NCT05089084 (PALISADE, BusinessWire) Manual	Phase 3	Familial chylomicronaemia syndrome	75	PlozasiranPlozasiran 25 mg	tfacdewgkz(nvocfdgmpa) = raguhgoqlu gagatovqss (caydjfbwun ) View more	Positive	02 Sep 2024
				PlozasiranPlozasiran 50 mg	tfacdewgkz(nvocfdgmpa) = wcwikkdpqr gagatovqss (caydjfbwun ) View more
NCT05089084 (PALISADE, Corporate Publications) Manual	Phase 3	Familial chylomicronaemia syndrome	75	Plozasiran 25 mg	ithnehfnro(ncwgdquwui) = jlykgarjhb dbzcritxwp (szopupcump ) Met View more	Positive	03 Jun 2024
				Plozasiran 50 mg	ithnehfnro(ncwgdquwui) = uhykxmaqah dbzcritxwp (szopupcump ) Met View more
NCT04998201 (MUIR, Pubmed) Manual	Phase 2	Hyperlipidemia, Familial Combined	353	Plozasiran 10 mg (quarterly doses)	layqytxugs(zbrzyhparm) = hjkgohjmxb rrscwzqpmh (jbybmxqhiw, -59.0 to -40.6) View more	Positive	28 May 2024
				Plozasiran 25 mg (quarterly doses)	layqytxugs(zbrzyhparm) = vxrowejtrk rrscwzqpmh (jbybmxqhiw, -65.1 to -46.8) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Plozasiran

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation